Guru Sonpavde

27.1k total citations · 6 hit papers
628 papers, 15.1k citations indexed

About

Guru Sonpavde is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Guru Sonpavde has authored 628 papers receiving a total of 15.1k indexed citations (citations by other indexed papers that have themselves been cited), including 375 papers in Surgery, 279 papers in Pulmonary and Respiratory Medicine and 240 papers in Oncology. Recurrent topics in Guru Sonpavde's work include Bladder and Urothelial Cancer Treatments (330 papers), Urinary and Genital Oncology Studies (176 papers) and Cancer Immunotherapy and Biomarkers (137 papers). Guru Sonpavde is often cited by papers focused on Bladder and Urothelial Cancer Treatments (330 papers), Urinary and Genital Oncology Studies (176 papers) and Cancer Immunotherapy and Biomarkers (137 papers). Guru Sonpavde collaborates with scholars based in United States, Canada and Italy. Guru Sonpavde's co-authors include Matthew D. Galsky, Thomas E. Hutson, Cora N. Sternberg, Joaquim Bellmunt, Ian F. Tannock, Toni K. Choueiri, Arnoud J. Templeton, Eitan Amir, Francisco Vera-Badillo and Priya Aneja and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Guru Sonpavde

596 papers receiving 14.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

2014 2.3k citations Guru Sonpavde et al. profile →
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

2021 670 citations Thomas Powles, Guru Sonpavde et al. profile →
Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy

2011 457 citations Guru Sonpavde, Joaquim Bellmunt et al. Journal of Clinical Oncology profile →
Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

2017 369 citations Guillermo de Velasco, Youjin Je et al. Cancer Immunology Research profile →
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology

2018 325 citations Guru Sonpavde et al. profile →
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

2023 84 citations Thomas Powles, Guru Sonpavde et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Guru Sonpavde

Since Specialization

Citations

This map shows the geographic impact of Guru Sonpavde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guru Sonpavde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guru Sonpavde more than expected).

Fields of papers citing papers by Guru Sonpavde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guru Sonpavde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guru Sonpavde. The network helps show where Guru Sonpavde may publish in the future.

Co-authorship network of co-authors of Guru Sonpavde

This figure shows the co-authorship network connecting the top 25 collaborators of Guru Sonpavde. A scholar is included among the top collaborators of Guru Sonpavde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guru Sonpavde. Guru Sonpavde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical perspective on management of key adverse events with sacituzumab govitecan 2025 ·The Oncologist ·(unknown), Guru Sonpavde, Paolo Tarantino, Maryam B. Lustberg, Hope S. Rugo	0
2	Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial 2025 ·Nature Communications ·Jeffrey Clarke, George R. Simon, Hirva Mamdani, Lin Gu, James E. Herndon, Thomas E. Stinchcombe, Neal Ready, Jeffrey Crawford, Guru Sonpavde, Stephen J. Balevic, Andrew B. Nixon, Michael J. Campa, Elizabeth B. Gottlin, Huihua Li, Ruchi Saxena, You‐Wen He, Scott Antonia, Edward F. Patz	7
3	The evolving treatment landscape of metastatic urothelial cancer 2024 ·Nature Reviews Urology ·Giandomenico Roviello, Matteo Santoni, Guru Sonpavde, Martina Catalano	11
4	Correlation of safety and efficacy of atezolizumab therapy across indications 2024 ·Journal for ImmunoTherapy of Cancer ·Gonzalo Durán-Pacheco, G. Scott Chandler, Vidya Maiya, Mark A. Socinski, Guru Sonpavde, Javier Puente, (unknown), Corey Carter, (unknown), (unknown), Jarushka Naidoo	3
5	REAL-WORLD ELIGIBILITY AND UTILIZATION OF AVELUMAB MAINTENANCE IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA 2024 ·Urologic Oncology Seminars and Original Investigations ·Alicia K. Morgans, Guru Sonpavde, (unknown), Phoebe Wright, Zsolt Hepp, Candice Willmon, Nancy N. Chang, (unknown), (unknown), Thomas Powles	0
6	A first-in-human (FIH), phase 1/2, dose-escalation, dose-optimization, and dose-expansion study of PARP1-selective inhibitor IMP1734 in participants with advanced solid tumors. 2024 ·Journal of Clinical Oncology ·Guru Sonpavde, Justin Call, Gerald S. Falchook, (unknown), Drew Rasco, Lan Liu, Tiantian Niu, (unknown), Congcong Zhang, Jarema Kochan, Sam Rebello, (unknown), Viola Chen, Suba Krishnan	2
7	Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial. 2024 ·Journal of Clinical Oncology ·Matt D. Galsky, Guru Sonpavde, Thomas Powles, Mélanie Claps, Mauricio Burotto, Michael Schenker, Juan Pablo Sade, Aristotelis Bamias, Philippe Beuzeboc, Jens Bedke, Jan Oldenburg, Yüksel Ürün, Dingwei Ye, Begoña P. Valderrama, Yoshihiko Tomita, Jeiry Filian, Lily Wang, Daniela Purcea, Michiel Simon Van Der Heijden	11
8	Phase 1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1 inhibitor, combined with pembrolizumab in patients with anti-PD1 resistant advanced solid tumors: Updated results of expansion part. 2024 ·Journal of Clinical Oncology ·Ulka N. Vaishampayan, Randy F. Sweis, Deepak Kilari, Ahmad A. Tarhini, Justin F. Gainor, Minal Barve, Guru Sonpavde, Meredith McKean, Jae‐Hyun Park, Sunil Babu, Yawen Ju, Lan Liu, Susan A. Henry, Lu Gan, Timothy A. Yap	1
9	Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (mUC) treatment-experienced (DAD) and with pembrolizumab (P) in treatment naïve UC (DAD-IO). 2024 ·Journal of Clinical Oncology ·Bradley A. McGregor, Lucia Kwak, Guru Sonpavde, Stephanie Berg, Toni K. Choueiri, Joaquim Bellmunt, Charlene Mantia	2
10	LBA7 Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: Results from the phase III CheckMate 901 trial 2023 ·Annals of Oncology ·Michiel S. van der Heijden, Guru Sonpavde, Thomas Powles, Andrea Necchi, Mauricio Burotto, Michael Schenker, (unknown), Aristotelis Bamias, Philippe Beuzeboc, Jens Bedke, Jan Oldenburg, (unknown), (unknown), Zhisong He, Begoña P. Valderrama, (unknown), (unknown), Daniela Purcea, Federico Nasroulah, Matt D. Galsky	9
11	660MO First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase I study (SGNB7H4V-001) 2023 ·Annals of Oncology ·Cesar A. Perez, Jason T. Henry, Nehal J. Lakhani, Justin Call, Erika Hamilton, Gerardo Colón‐Otero, Jennifer R. Diamond, Bert H. O’Neil, (unknown), Guru Sonpavde, (unknown), Arif Awan, Elisa Fontana, Pengfei Xu, Fumin Zhang, (unknown), Amita Patnaik	9
12	Circulating and urinary tumour DNA in urothelial carcinoma — upper tract, lower tract and metastatic disease 2023 ·Nature Reviews Urology ·Kyle Rose, (unknown), Joshua J. Meeks, Bishoy M. Faltas, Guru Sonpavde, Seth P. Lerner, Jeffrey S. Ross, Philippe E. Spiess, G. Daniel Grass, Rohit Jain, Ashish M. Kamat, Aram Vosoughi, Liang Wang, Xuefeng Wang, Roger Li	27
13	Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent 2021 ·Molecular Cancer Therapeutics ·Eddy S. Yang, Amin H. Nassar, Elio Adib, Opeyemi A. Jegede, Sarah Abou Alaiwi, (unknown), David A. Braun, Mahsa Zarei, Heng Du, Sumanta K. Pal, Gurudatta Naik, Guru Sonpavde	6
14	Muscle-invasive Urothelial Cancer: Association of Mutational Status with Metastatic Pattern and Survival 2020 ·Radiology ·Francesco Alessandrino, (unknown), Amin H. Nassar, Rahul Gujrathi, Stuart G. Silverman, Guru Sonpavde, Atul B. Shinagare	8
15	Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis 2020 ·Critical Reviews in Oncology/Hematology ·Carlo Buonerba, Matteo Ferro, Pasquale Dolce, Felice Crocetto, Antonio Verde, Giuseppe Lucarelli, Luca Scafuri, Sergio Facchini, (unknown), Alfredo Marinelli, Daniela Terracciano, Liliana Montella, Nicola Longo, Ciro Imbimbo, Vincenzo Mirone, Giuseppe Di Lorenzo, Sabino De Placido, Guru Sonpavde	36
16	Loss of FOXP3 and TSC1 Accelerates Prostate Cancer Progression through Synergistic Transcriptional and Posttranslational Regulation of c-MYC 2019 ·Cancer Research ·Lianpin Wu, (unknown), Shi Wei, (unknown), (unknown), Gurudatta Naik, Sejong Bae, Margaret Liu, Wei‐Hsiung Yang, Guru Sonpavde, Runhua Liu, Lizhong Wang	30
17	Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancer 2019 ·Cancer ·Guru Sonpavde, Neeraj Agarwal, Gregory R. Pond, Rebecca J. Nagy, Roberto Nussenzveig, Andrew W. Hahn, Oliver Sartor, Theodore Stewart Gourdin, Lakshminarayanan Nandagopal, Elisa M. Ledet, Gurudatta Naik, Andrew J. Armstrong, Jue Wang, Mehmet Asım Bilen, Shilpa Gupta, Petros Grivas, Sumanta K. Pal, Richard B. Lanman, AmirAli Talasaz, Michelle M. Lilly	41
18	Integrative Epigenetic and Gene Expression Analysis of Renal Tumor Progression to Metastasis 2018 ·Molecular Cancer Research ·Hyeyoung Nam, Darshan S. Chandrashekar, Anirban Kundu, Sandeep B. Shelar, (unknown), Guru Sonpavde, Gurudatta Naik, Pooja Ghatalia, Carolina B. Livi, Sooryanarayana Varambally, Sunil Sudarshan	34
19	Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites 2018 ·Clinical Cancer Research ·Amin H. Nassar, Renato Umeton, Jaegil Kim, (unknown), Lauren C. Harshman, Eliezer M. Van Allen, Mark A. Preston, Fei Dong, Joaquim Bellmunt, Kent W. Mouw, Toni K. Choueiri, Guru Sonpavde, David J. Kwiatkowski	87
20	Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients breakdown → 2017 ·Cancer Immunology Research ·Guillermo de Velasco, Youjin Je, Dominick Bossé, Mark M. Awad, Patrick A. Ott, Raphael Brandão Moreira, Fabio A.B. Schutz, Joaquim Bellmunt, Guru Sonpavde, F. Stephen Hodi, Toni K. Choueiri	369

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact